title: [G-CSF and GM-CSF in treatment of neutropaenia after chemotherapy in children with neoplasms].
abstract: A total number of 608 cycles of G-CSF and/or GM-CSF was applied in 280 patients aged from 6 months to 20 years during neutropaenia associated with chemotherapy of children's neoplasms (NHL-124, NBL-42, RMS-36, Nephroblastoma-18, Osteosarcoma-17, Ewing's Sarcoma-14, Hepatoblastoma-6, Neurofibrosarcoma-6, PNET-5, Medulloblastoma-3, Fibrohistiocytoma-3, Angiosarcoma-2, other - 4). G-CSF - Neupogen (Filgastrim, Hoffman La Roche - 492 cycles) and GM-CSF - Leucomax (Molgramostim, Shering Plough - 116 cycles) were administered 5 mg/kg/day s.c. Forty one children with malignancies (NHL -21 cases, solid tumours -17) treated before cytokines were in use served as a control group. Our study demonstrated that G-CSF and GM-CSF therapy, gives a shorter period of neutropaenia, reduction of the number of febrile days, decreased frequency of infection and shortened its duration.
authors.affiliation: Katedra i Klinika Hematologii i Chorób Rozrostowych Dzieci, 50-345 Wroclaw, Bujwida 44, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: B
authors.initials: B
authors.lastname: Rosińska
authors.forename: J
authors.initials: J
authors.lastname: Wecławek-Tompol
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: A
authors.initials: A
authors.lastname: Balcerska
authors.forename: W
authors.initials: W
authors.lastname: Balwierz
authors.forename: H
authors.initials: H
authors.lastname: Bubala
authors.forename: K
authors.initials: K
authors.lastname: Drabko
authors.forename: A
authors.initials: A
authors.lastname: Eliasinska
authors.forename: M
authors.initials: M
authors.lastname: Kedziora
authors.forename: D
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: B
authors.initials: B
authors.lastname: Sopylo
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: M J
authors.initials: MJ
authors.lastname: Stefaniak
authors.forename: E
authors.initials: E
authors.lastname: Stańczak
authors.forename: D
authors.initials: D
authors.lastname: Stencel
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
authors.forename: A
authors.initials: A
authors.lastname: Płoszyńska
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor